PD-1 blockade promotes epitope spreading in anticancer CD8+ T cell responses by preventing fratricidal death of subdominant clones to relieve immunodomination

Arash Memarnejadian, Courtney E. Meilleur, Christopher R. Shaler, Khashayarsha Khazaie, Jack R. Bennink, Todd Schell, S. M.Mansour Haeryfar

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The interactions between programmed death-1 (PD-1) and its ligands hamper tumor-specific CD8+ T cell (TCD8) responses, and PD-1-based 'checkpoint inhibitors' have shown promise in certain cancers, thus revitalizing interest in immunotherapy. PD-1- targeted therapies reverse TCD8 exhaustion/anergy. However, whether they alter the epitope breadth of TCD8 responses remains unclear. This is an important question because subdominant TCD8 are more likely than immunodominant clones to escape tolerance mechanisms and may contribute to protective anticancer immunity. We have addressed this question in an in vivo model of TCD8 responses to well-defined epitopes of a clinically relevant oncoprotein, large T Ag. We found that unlike other coinhibitory molecules (CTLA-4, LAG-3, TIM-3), PD-1 was highly expressed by subdominant TCD8, which correlated with their propensity to favorably respond to PD-1/PD-1 ligand-1 (PD-L1)-blocking Abs. PD-1 blockade increased the size of subdominant TCD8 clones at the peak of their primary response, and it also sustained their presence, thus giving rise to an enlarged memory pool. The expanded population was fully functional as judged by IFN-g production and MHC class I-restricted cytotoxicity. The selective increase in subdominant TCD8 clonal size was due to their enhanced survival, not proliferation. Further mechanistic studies utilizing peptide-pulsed dendritic cells, recombinant vaccinia viruses encoding full-length T Ag or epitope mingenes, and tumor cells expressing T Ag variants revealed that anti-PD-1 invigorates subdominant TCD8 responses by relieving their lysisdependent suppression by immunodominant TCD8. To our knowledge, our work constitutes the first report that interfering with PD-1 signaling potentiates epitope spreading in tumor-specific responses, a finding with clear implications for cancer immunotherapy and vaccination.

Original languageEnglish (US)
Pages (from-to)3348-3359
Number of pages12
JournalJournal of Immunology
Volume199
Issue number9
DOIs
StatePublished - Nov 1 2017

Fingerprint

Epitopes
Clone Cells
T-Lymphocytes
Neoplasms
Immunotherapy
Ligands
Vaccinia virus
Oncogene Proteins
Dendritic Cells
Immunity
Vaccination
Peptides
Population

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology

Cite this

Memarnejadian, Arash ; Meilleur, Courtney E. ; Shaler, Christopher R. ; Khazaie, Khashayarsha ; Bennink, Jack R. ; Schell, Todd ; Haeryfar, S. M.Mansour. / PD-1 blockade promotes epitope spreading in anticancer CD8+ T cell responses by preventing fratricidal death of subdominant clones to relieve immunodomination. In: Journal of Immunology. 2017 ; Vol. 199, No. 9. pp. 3348-3359.
@article{529794ca472745189ce45c962a026519,
title = "PD-1 blockade promotes epitope spreading in anticancer CD8+ T cell responses by preventing fratricidal death of subdominant clones to relieve immunodomination",
abstract = "The interactions between programmed death-1 (PD-1) and its ligands hamper tumor-specific CD8+ T cell (TCD8) responses, and PD-1-based 'checkpoint inhibitors' have shown promise in certain cancers, thus revitalizing interest in immunotherapy. PD-1- targeted therapies reverse TCD8 exhaustion/anergy. However, whether they alter the epitope breadth of TCD8 responses remains unclear. This is an important question because subdominant TCD8 are more likely than immunodominant clones to escape tolerance mechanisms and may contribute to protective anticancer immunity. We have addressed this question in an in vivo model of TCD8 responses to well-defined epitopes of a clinically relevant oncoprotein, large T Ag. We found that unlike other coinhibitory molecules (CTLA-4, LAG-3, TIM-3), PD-1 was highly expressed by subdominant TCD8, which correlated with their propensity to favorably respond to PD-1/PD-1 ligand-1 (PD-L1)-blocking Abs. PD-1 blockade increased the size of subdominant TCD8 clones at the peak of their primary response, and it also sustained their presence, thus giving rise to an enlarged memory pool. The expanded population was fully functional as judged by IFN-g production and MHC class I-restricted cytotoxicity. The selective increase in subdominant TCD8 clonal size was due to their enhanced survival, not proliferation. Further mechanistic studies utilizing peptide-pulsed dendritic cells, recombinant vaccinia viruses encoding full-length T Ag or epitope mingenes, and tumor cells expressing T Ag variants revealed that anti-PD-1 invigorates subdominant TCD8 responses by relieving their lysisdependent suppression by immunodominant TCD8. To our knowledge, our work constitutes the first report that interfering with PD-1 signaling potentiates epitope spreading in tumor-specific responses, a finding with clear implications for cancer immunotherapy and vaccination.",
author = "Arash Memarnejadian and Meilleur, {Courtney E.} and Shaler, {Christopher R.} and Khashayarsha Khazaie and Bennink, {Jack R.} and Todd Schell and Haeryfar, {S. M.Mansour}",
year = "2017",
month = "11",
day = "1",
doi = "10.4049/jimmunol.1700643",
language = "English (US)",
volume = "199",
pages = "3348--3359",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "9",

}

PD-1 blockade promotes epitope spreading in anticancer CD8+ T cell responses by preventing fratricidal death of subdominant clones to relieve immunodomination. / Memarnejadian, Arash; Meilleur, Courtney E.; Shaler, Christopher R.; Khazaie, Khashayarsha; Bennink, Jack R.; Schell, Todd; Haeryfar, S. M.Mansour.

In: Journal of Immunology, Vol. 199, No. 9, 01.11.2017, p. 3348-3359.

Research output: Contribution to journalArticle

TY - JOUR

T1 - PD-1 blockade promotes epitope spreading in anticancer CD8+ T cell responses by preventing fratricidal death of subdominant clones to relieve immunodomination

AU - Memarnejadian, Arash

AU - Meilleur, Courtney E.

AU - Shaler, Christopher R.

AU - Khazaie, Khashayarsha

AU - Bennink, Jack R.

AU - Schell, Todd

AU - Haeryfar, S. M.Mansour

PY - 2017/11/1

Y1 - 2017/11/1

N2 - The interactions between programmed death-1 (PD-1) and its ligands hamper tumor-specific CD8+ T cell (TCD8) responses, and PD-1-based 'checkpoint inhibitors' have shown promise in certain cancers, thus revitalizing interest in immunotherapy. PD-1- targeted therapies reverse TCD8 exhaustion/anergy. However, whether they alter the epitope breadth of TCD8 responses remains unclear. This is an important question because subdominant TCD8 are more likely than immunodominant clones to escape tolerance mechanisms and may contribute to protective anticancer immunity. We have addressed this question in an in vivo model of TCD8 responses to well-defined epitopes of a clinically relevant oncoprotein, large T Ag. We found that unlike other coinhibitory molecules (CTLA-4, LAG-3, TIM-3), PD-1 was highly expressed by subdominant TCD8, which correlated with their propensity to favorably respond to PD-1/PD-1 ligand-1 (PD-L1)-blocking Abs. PD-1 blockade increased the size of subdominant TCD8 clones at the peak of their primary response, and it also sustained their presence, thus giving rise to an enlarged memory pool. The expanded population was fully functional as judged by IFN-g production and MHC class I-restricted cytotoxicity. The selective increase in subdominant TCD8 clonal size was due to their enhanced survival, not proliferation. Further mechanistic studies utilizing peptide-pulsed dendritic cells, recombinant vaccinia viruses encoding full-length T Ag or epitope mingenes, and tumor cells expressing T Ag variants revealed that anti-PD-1 invigorates subdominant TCD8 responses by relieving their lysisdependent suppression by immunodominant TCD8. To our knowledge, our work constitutes the first report that interfering with PD-1 signaling potentiates epitope spreading in tumor-specific responses, a finding with clear implications for cancer immunotherapy and vaccination.

AB - The interactions between programmed death-1 (PD-1) and its ligands hamper tumor-specific CD8+ T cell (TCD8) responses, and PD-1-based 'checkpoint inhibitors' have shown promise in certain cancers, thus revitalizing interest in immunotherapy. PD-1- targeted therapies reverse TCD8 exhaustion/anergy. However, whether they alter the epitope breadth of TCD8 responses remains unclear. This is an important question because subdominant TCD8 are more likely than immunodominant clones to escape tolerance mechanisms and may contribute to protective anticancer immunity. We have addressed this question in an in vivo model of TCD8 responses to well-defined epitopes of a clinically relevant oncoprotein, large T Ag. We found that unlike other coinhibitory molecules (CTLA-4, LAG-3, TIM-3), PD-1 was highly expressed by subdominant TCD8, which correlated with their propensity to favorably respond to PD-1/PD-1 ligand-1 (PD-L1)-blocking Abs. PD-1 blockade increased the size of subdominant TCD8 clones at the peak of their primary response, and it also sustained their presence, thus giving rise to an enlarged memory pool. The expanded population was fully functional as judged by IFN-g production and MHC class I-restricted cytotoxicity. The selective increase in subdominant TCD8 clonal size was due to their enhanced survival, not proliferation. Further mechanistic studies utilizing peptide-pulsed dendritic cells, recombinant vaccinia viruses encoding full-length T Ag or epitope mingenes, and tumor cells expressing T Ag variants revealed that anti-PD-1 invigorates subdominant TCD8 responses by relieving their lysisdependent suppression by immunodominant TCD8. To our knowledge, our work constitutes the first report that interfering with PD-1 signaling potentiates epitope spreading in tumor-specific responses, a finding with clear implications for cancer immunotherapy and vaccination.

UR - http://www.scopus.com/inward/record.url?scp=85032023930&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032023930&partnerID=8YFLogxK

U2 - 10.4049/jimmunol.1700643

DO - 10.4049/jimmunol.1700643

M3 - Article

VL - 199

SP - 3348

EP - 3359

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 9

ER -